In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA

Neuroscience Letters

Volumn 627, Issue , 2016, Pages 216-221

  Kutschenko, Anna ^a   Manig, Anja ^a   Reinert, Marie Christine ^a   Mönnich, Angelika ^a   Liebetanz, David ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

AbobotulinumtoxinA; IncobotulinumtoxinA; Neurotoxic potency; OnabotulinumtoxinA; Volume dependency; Wheel running performance

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; SODIUM CHLORIDE; NEUROTOXIN;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; GASTROCNEMIUS MUSCLE; IN VIVO STUDY; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARESIS; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; HINDLIMB; MOTOR ACTIVITY;

ANIMALS; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; HINDLIMB; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROTOXINS; PARESIS;

EID: 84976344606     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.06.001     Document Type: Article

References (29)

1. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 1982, 46:86-94.
2. Frevert J., Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance. Biologics 2010, 4:325-332.
3. Chen J.J., Dashtipour K. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. Pharmacotherapy 2013, 33:304-318.
4. Frevert J. Content of botulinum neurotoxin in botox/vistabel dysport/azzalure, and xeomin/bocouture. Drugs R D 2010, 10:67-73.
5. Schantz E.F., Johnson E.A. Dose standardization of botulinum toxin. Lancet 1990, 335:421.
6. Brown M., Nicholson G., Ardila M.C., Satorius A., Broide R.S., Clarke K., Hunt T., Francis J. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. J. Neural. Transm. 2013, 120:291-298.
7. Dressler D., Mander G., Fink K. Measuring the potency labeling of onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in an LD50 assay. J. Neural. Transm. 2012, 119:13-15.
8. Hunt T., Clarke K. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin. Neuropharmacol. 2009, 32:28-31.
9. Rummel A., Mahrhold S., Bigalke H., Binz T. The HCC-domain of botulinum neurotoxin A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 2004, 51:631-643.
10. Dressler D. Comparing botox and xeomin for axillar hyperhidrosis. J. Neural. Transm. 2010, 117:317-319.
11. ®)). J. Neural. Transm. 2014, 121:29-31.
12. Jost W.H., Kohl A., Brinkmann S., Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J. Neural. Transm. 2005, 112:905-913.
13. Ravenni R., De Grandis D., Mazza A. Converison ratio between dysport and botox in clinical practice: an overview of available evidence. Neurol. Sci. 2013, 34:1043-1048.
14. Roggenkämper P., Jost W.H., Bihari K., Comes G., Grafe S., NT 201 Blepharospasm Study Team Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J. Neural. Transm. 2006, 113:303-312.
15. Chung M.E., Song D.H., Park J.H. Comparative study of biological activity of four botulinum toxin type A preparations in mice. Dermatol. Surg. 2013, 29:155-164.
16. Ranoux D., Gury C., Fondarai J., Mas J.L., Zuber M. Respective potencies of Botox and Dysport: a double blind randomized, crossover study in cervical dystonia. J. Neurol. Neurosurg. Psychiatry 2002, 72:459-462.
17. Wohlfarth K., Sycha T., Ranoux D., Naver H., Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?. Curr. Med. Res. Opin. 2009, 25:1573-1584.
18. Rosales R.L., Bigalke H., Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur. J. Neurol. 2006, 13:2-10.
19. Pearce L.B., Borodic G.E., First E.F., MacCallum R.D. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol. Appl. Pharmacol. 1994, 128:69-77.
20. Bigalke H., Wohlfarth K., Irmer A., Dengler R. Botulinum A toxin: dysport improvement of biological availability. Exp. Neurol. 2001, 168:162-170.
21. Francisco G.E. Botulinum toxin: dosing and dilution. Am. J. Phys. Med. Rehabil. 2004, 83:S30-S37.
22. Gracies J.M., Lugassy M., Weisz D.J., Vecchio M., Flanagan S., Simpson D.M. Botulinum toxin in dilution and endplate targeting in spasticity: a double-blind controlled study. Arch. Phys. Med. Rehabil. 2009, 90:9-16.
23. Kim H.S., Hwang J.H., Jeong S.T., Lee Y.T., Lee P.K., Suh Y.L., Shim J.S. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev. Med. Child. Neurol. 2003, 45:200-206.
24. Ramirez-Castaneda J., Jankovic J., Comella C., Dashtipour K., Fernandez H.H., Mari Z. Diffusion spread, and migration of botulinum toxin. Mov. Disord. 2013, 28:1775-1783.
25. Kutschenko A., Reinert M.C., Klinker F., Paulus W., Hesse S., Liebetanz D. Botulinum toxin-induced focal paresis in mice is unaffected by muscle activity. Muscle Nerve 2011, 44:930-936.
26. Kutschenko A., Reinert M.C., Klinker F., Paulus W., Hesse S., Liebetanz D. Accurate quantification of tetanus neurotoxin-induced focal spasticity in mice using complex running wheels. J. Neurosci. Methods 2012, 205:45-48.
27. Liebetanz D., Merkler D. Effects of commissural de- and remyelination on motor skill behavior in the cuprizone mouse model of multiple sclerosis. Exp. Neurol. 2006, 202:217-224.
28. Hu G.C., Chuang Y.C., Liu J.P., Chien K.L., Chen Y.M., Chen Y.F. Botulinum toxin (dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: a randomized trial comparing two injection volumes. Clin. Rehabil. 2009, 23:64-71.
29. Pathak M.S., Nguyen H.T., Graham H.K., Moore A.P. Management of spasticicy in adults: practical application of botulinum toxin. Eur. J. Neurol. 2006, 13:42-50.